Piplartine as an Innovative Natural Product With Dual Antiparasitic and Immunomodulatory Actions. [PDF]
Fukui-Silva L +3 more
europepmc +1 more source
Inhibition of Aurora B induces senescence and potentiates immunotherapy in hepatocellular carcinoma. [PDF]
Wu S +8 more
europepmc +1 more source
Proteasome: Role in T Cell Function Regulation. [PDF]
Tang D, Wu X, Lei JH, Qiao Y, Deng CX.
europepmc +1 more source
The immunoproteasome as a neuroimmune hub in the central nervous system: from proteostasis stress to inflammatory pathology. [PDF]
Zhao H, Liu Y, Chen X.
europepmc +1 more source
Immunoproteasome remodeling in senescing human macrophages reveals the loss of PA28αβ capping as a hallmark of immunosenescence. [PDF]
Monittola F +13 more
europepmc +1 more source
Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome. [PDF]
Demel UM +19 more
europepmc +1 more source
Cytokine-Mediated Plasticity in the Molecular Requirements for Peptide-Loading Complex Formation and Antigen Presentation. [PDF]
Aranha R +6 more
europepmc +1 more source
Related searches:
Immunoproteasomes and immunosenescence
Ageing Research Reviews, 2003Aging is a complex process which is accompanied with the decline and the reshaping of different functions of the body. In particular the immune system is characterized, during ageing (immunosenescence) by a remodeling of innate immunity (well preserved, up-regulated) and clonotypical immunity (severely altered) and by the occurrence of a chronic ...
Mishto M. +5 more
openaire +3 more sources
Proteasomes and immunoproteasomes.
Rivista di biologia, 2011In eukaryotic cells, the protein degradation is a highly regulated and selective process. Membrane-associated or extracellular proteins are degraded in lysosomes, whereas intracellular protein dismantling is primarily non-lysosomal, being realized by complex, not-membrane enclosed and energy-dependent effectors, the proteasomes, localized in both ...
Fietta, Pieranna, Delsante, Giovanni
openaire +2 more sources
Modern treatment strategies for the maintenance of allograft acceptance frequently target ubiquitously-expressed pathways, leading to significant side-effects and poor long-term allograft outcomes. Constitutive proteasome inhibitors, which have recently been introduced for the treatment of antibody-mediated rejection, target the ubiquitously-expressed ...
Eskandari, S. K. +3 more
openaire +1 more source

